Educational resources

Guidelines in Practice has developed a range of educational resources—including animations, formulary decision guides, implementation checklists, supplements, and webinars—to support you with your learning and implementation of best practice. Items may contain pharmaceutical promotional information.

eLearning module index image

The importance of reducing cardiovascular risk in patients with type 2 diabetes

Promotional material from the Boehringer Ingelheim and Lilly Alliance

This eLearning module has been commissioned and funded by the Boehringer Ingelheim and Lilly Alliance and developed in partnership with Guidelines in Practice and Guidelines Learning. Products are discussed. This eLearning module is intended for healthcare professionals.
View Jardiance® (empagliflozin) prescribing and adverse event reporting information for Great Britain or Northern Ireland
PC-GB-105238  September 2021

Hands with rheumatoid arthritis_AS

Disease-modifying anti-rheumatic drugs (DMARDS) guidelines: a focus on methotrexate guidance in clinical practice

Commissioned by Accord UK Ltd

Information intended for UK healthcare professionals only. This webinar was initiated and commissioned by Accord-UK Ltd and developed in partnership with Guidelines in Practice.
View Methofill® (methotrexate) pre-filled injector and pre-filled syringe prescribing information and adverse event reporting information here
View the Summary of Product Characteristics for Folic Acid 5mg Tablets; Legal Cat POM; NHS List price 90p
UK-02645
Date of preparation: September 2021

Trajenta webinar index

Dipeptidyl peptidase-4 inhibitors—still a major player in type 2 diabetes care

Commissioned by Boehringer Ingelheim Limited

This promotional webinar has been initiated and commissioned by Boehringer Ingelheim Limited and organised in partnership with Guidelines in Practice.
View Trajenta® (linagliptin) prescribing and adverse events reporting information for:
Great Britain 
Northern Ireland
PC-GB-103485 | July 2021

asthma inhaler

The importance of inhaler choice

Commissioned by Boehringer Ingelheim Limited

Information intended for UK healthcare professionals only. This promotional webinar was commissioned and funded by Boehringer Ingelheim and developed in partnership with Guidelines in Practice
View prescribing information here.
PC-GB-104812
Date of preparation: June 2021

Advertisement

Macmillan Guidelines 3000x2000 Clinical Native

Specialist support for your patients with cancer - Macmillan’s Support Line can help.

This is promotional material from Macmillan Cancer Support.

From clinical information to emotional support, and advice on money and work, the Macmillan Support Line will do whatever it takes to support your patients. Learn more here.

CMA index image

Cow’s Milk Allergy (CMA) and The Allergic March

Commissioned and funded by Reckitt

This promotional animation has been commissioned and funded by Reckitt and developed in partnership with Guidelines in Practice.
RB-R-9342 November 2021

Decompensated cirrhosis animation image

Animation on the decompensated cirrhosis care bundle—the first 24 hours

Commissioned by Norgine Pharmaceuticals Limited

This animation has been commissioned and funded by Norgine Pharmaceuticals Limited and developed in partnership with Guidelines in Practice.
UKE-COR-NP-2100080  Date of preparation: October 2021

Trajenta animation updated index image

Prescribing a dipeptidyl peptidase-4 inhibitor in adults with type 2 diabetes and comorbidities

Commissioned by Boehringer Ingelheim Limited

This animation has been commissioned and funded by Boehringer Ingelheim Limited and developed in partnership with Guidelines in Practice.
View Trajenta (linagliptin) adverse event reporting and prescribing information for Great Britain or Northern Ireland
PC-GB-105090 Date of preparation: October 2021

Doctor writing AS 216244365 Andrey Popov web optimised

In conversation: barriers to implementation of the NHS restructure and future opportunities

In the final In conversation video on the NHS restructure, Dr Karen Kirkham and Dr Anthony Cunliffe explore barriers to the success of the changes

Doctor + clipboard working on laptop

In conversation: potential benefits of the NHS restructure for practice and patients

In the second In conversation video on the NHS reorganisation, Dr Karen Kirkham and Dr Anthony Cunliffe talk about the emerging benefits of the changes

Doctor at computer660x440

In conversation: specifics and context of the NHS restructure

By Dr Karen Kirkham and Dr Anthony Cunliffe

In the first of a new series of In conversation videos, Dr Karen Kirkham and Dr Anthony Cunliffe discuss the details and backdrop of forthcoming changes to the NHS in England

Bronchiectasis video index image edit

Five things you need to know about… bronchiectasis

By Dr Kevin Gruffydd-Jones

In the first of a new series of videos, Dr Kevin Gruffydd-Jones highlights five things you need to know about bronchiectasis

5-minute video_Chronic respiratory conditions and COVID-19-v2

NICE guidance on respiratory conditions and COVID-19: 5-minute video

By Dr Kevin Gruffydd-Jones

Dr Kevin Gruffydd-Jones highlights important things you need to know about managing respiratory conditions in a COVID-19 context

FINAL Feraccru FDG images

FERACCRU® (ferric maltol) 30 mg hard capsules

Commissioned by Norgine Pharmaceuticals Limited

Information intended for UK healthcare professionals only. This formulary decision guide is promotional and was developed from content provided by Norgine Pharmaceuticals Limited in a format developed by Guidelines in Practice (contains promotional information).
View FERACCRU®  (ferric maltol) prescribing information and adverse event reporting information here
UK-HAE-FER-2100127
Date of preparation: December 2021

Jardiance HF FDG_index image

Jardiance® (empagliflozin) film-coated tablets for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF)

Promotional material from the Boehringer Ingelheim and Lilly Alliance

This formulary decision guide was commissioned by the Boehringer Ingelheim and Lilly Alliance. 
View Jardiance® (empagliflozin) prescribing and adverse event reporting information for Great Britain and Northern Ireland.
PC-GB-105819 October 2021

Klisyri (tirbanibulin) FDG - digital

Klisyri▼ (tirbanibulin) 10 mg/g ointment

Commissioned by Almirall Ltd

This formulary decision guide was developed from content provided by Almirall Ltd in a format developed by Guidelines in Practice. It was commissioned by Almirall Ltd, who carried out full medical approval to ensure compliance with regulations.
View prescribing and adverse event reporting information
UK-KLI-2100017 | Date of preparation: October 2021

20210927 Sixmo FDG new image

Sixmo®▼ (buprenorphine) 74.2 mg implant

Commissioned by Accord UK Ltd

Information intended for UK healthcare professionals only. This formulary decision guide was developed from content provided by Accord Healthcare Limited in a format developed by Guidelines in Practice.
View prescribing information and adverse event reporting information.
UK-03417
Date of preparation: October 2021

Ipinnia XL (ropinirole hydrochloride) FDG

Ipinnia® XL (ropinirole hydrochloride) prolonged-release tablets

Commissioned by Ethypharm UK Ltd

This formulary decision guide was commissioned by Ethypharm and developed from content provided by Ethypharm in a format developed by Guidelines in Practice.
View prescribing and adverse event reporting information
For UK healthcare professionals only.
UK-IPN-13  Date of preparation: September 2021

Xaggitin XL (methylphenidate hydrochloride) FDG

Xaggitin XL (methylphenidate hydrochloride) prolonged-release tablets

Commissioned by Ethypharm UK Ltd

This formulary decision guide was commissioned by Ethypharm and developed from content provided by Ethypharm in a format developed by Guidelines in Practice.
View prescribing and adverse event reporting information
For UK healthcare professionals only.
UK-XAG-20  Date of preparation: July 2021

Steglatro FDG inxed image

Steglatro®▼ (Ertugliflozin)

Commissioned by MSD UK Ltd

This formulary decision guide was developed from content provided by MSD UK Ltd in a format developed by Guidelines in Practice.
Prescribing Information (Great Britain) & (Northern Ireland), and Adverse Event Reporting Information
GB-STE-00433 | June 2021

FINAL index image

Trurapi▼ (insulin aspart 100 units/ml)

Commissioned by Sanofi Ltd

This formulary decision guide was developed from content provided by Sanofi Ltd in a format developed by Guidelines in Practice.
View prescribing and adverse event reporting information
MAT-GB-2101070(v2.0) | Date of preparation: July 2021

Colitis supplement Index image

Identification and management of colitis in primary care—practical tips and considerations

Commissioned and funded by Ferring Pharmaceuticals

This supplement has been commissioned and funded by Ferring Pharmaceuticals and developed in partnership with Guidelines in Practice
View prescribing and adverse event reporting information for Cortiment® (budesonide) and Pentasa® (mesalazine)
UK-GAS-2100137 December 2021

FINAL Obesity supplement image cover

Overcoming challenges in managing obesity in primary care

Funded by Novo Nordisk Limited

Information intended for UK healthcare professionals only. This supplement has been funded through an arm’s-length sponsorship by Novo Nordisk Limited. Guidelines in Practice approached Novo Nordisk Limited to fund the production of the supplement.
Date of preparation: December 2021

NICE AF RTD - digital

NICE atrial fibrillation: diagnosis and management guideline (NG196) update—treatment considerations for direct-acting oral anticoagulants (DOACs)

Commissioned by Bayer Plc

Information intended for UK healthcare professionals only. This round-table discussion supplement has been commissioned and funded by Bayer plc and developed in partnership with Guidelines in Practice.
View Xarelto® (rivaroxaban) adverse event reporting and prescribing information
PP-XAR-GB-2369
Date of preparation: November 2021

FINAL Ipsen supplement image

Exploring decisions surrounding the optimisation of Androgen Deprivation Therapy (ADT) use for appropriate prostate cancer (PCa) patients in the NHS in light of COVID-19

Commissioned by Ipsen UK Ltd

Information intended for UK healthcare professionals only. This promotional supplement has been commissioned and funded by Ipsen UK Ltd and developed in partnership with Guidelines in Practice.
View DECAPEPTYL® SR (triptorelin) 3mg, DECAPEPTYL® SR (triptorelin) 11.25mg and DECAPEPTYL® SR (triptorelin) 22.5mg prescribing information and adverse event reporting information here
TRI-UK-004677
Date of preparation: October 2021

Front cover image

The unrecognised epidemic of vitamin D deficiency in Black, Asian and Minority Ethnic (BAME) groups: a consensus document

Commissioned by STADA incorporating Thornton & Ross

Information intended for UK healthcare professionals only. This supplement has been commissioned and funded by STADA incorporating Thornton & Ross, who provided the content.
TR-088d  Date of preparation: August 2021

Index image

Guideline for the managed introduction of biosimilar bolus insulin in individuals with type 2 diabetes

Supported by an educational grant from Sanofi Ltd

This working party guideline was developed by a multidisciplinary expert panel: Down S et al with the support of an educational grant from Sanofi Ltd

FINAL index image

Methofill® (methotrexate) SelfDose for the treatment of adult patients with rheumatoid arthritis, Crohn’s disease, and psoriasis*

Commissioned by Accord UK Ltd

Intended for UK Healthcare professionals only.
This promotional supplement has been commissioned and funded by Accord-UK Ltd and developed in partnership with Guidelines in Practice.
Click here for Methofill® (methotrexate) prescribing information and adverse event reporting
For full indications, please consult the summary of product characteristics.
UK-03037 | Date of preparation: May 2021

Front cover 20201202 Plenvu supplement December 2020 PI

Real-world usage study and survey of oral bowel cleansing for colonoscopy in Dudley, UK

Commissioned by Norgine Pharmaceuticals Limited

This supplement has been commissioned by Norgine Pharmaceuticals Limited and contains promotional information. Information for healthcare professionals only.
Click here for PLENVU® (macrogol 3350, sodium ascorbate, ascorbic acid, sodium sulfate anhydrous, potassium chloride, sodium chloride) Prescribing and Adverse Event Reporting.
Click here for MOVIPREP® ((macrogol 3350, sodium sulfate anhydrous, ascorbic acid, sodium ascorbate, sodium chloride, and potassium chloride) Prescribing and Adverse Event Reporting.
Click here for KLEAN-PREP (macrogol 3350, anhydrous sodium sulfate, sodium bicarbonate, sodium chloride, potassium chloride) Prescribing and Adverse Event Reporting.
UK-GE-PLV-2000027
Date of preparation: February 2021

Emollient supplement_Index image

Recommending emollients for patients with atopic dermatitis or dry skin conditions

Commissioned by L’Oréal (UK) Limited

This supplement has been commissioned and funded by L’Oréal (UK) Limited and developed in partnership with Guidelines
Date of preparation: January 2021

Diabetes equipment vector

Showcasing local best practice in diabetes

This Guidelines in Practice supplement aims to showcase local best practice in the diagnosis and management of diabetes. The supplement includes articles from three local initiatives that have developed their own guidance or demonstrated improvements in different areas of diabetes care:

Malnutrition supplement

Identification and management of patients with malnutrition

Commissioned by Alliance Pharmaceuticals Ltd

This supplement has been commissioned and funded by Alliance Pharmaceuticals Ltd and developed in partnership with Guidelines in Practice.

Biosimilar insulin WPG

Guideline for the managed introduction of biosimilar basal insulin

Supported by an educational grant from Mylan

This working party guideline was developed by a multidisciplinary expert panel: Down S et al with the support of a grant from Mylan.

NICE acne checklist index image

Implementing the NICE guideline on the management of acne vulgaris

Supported by an educational grant from Galderma UK Ltd

Information intended for UK healthcare professionals only.

NICE Atrial fibrillation checklist

Checklist on the implementation of the NICE guideline on atrial fibrillation: diagnosis and management

Commissioned and funded by Daiichi Sankyo

This implementation checklist has been commissioned and funded by Daiichi Sankyo UK and developed in partnership with Guidelines in Practice.
View LIXIANA (edoxaban) prescribing and adverse event reporting information
EDX/21/0535 July 2021

FINAL Obesity algorithm checklist image

Implementing the Guidelines algorithm on managing obesity in primary care

Supported by an educational grant from Novo Nordisk Limited

Guidelines in Practice approached Novo Nordisk Ltd for an educational grant to support the production of an implementation checklist. Information intended for UK healthcare professionals only.
Date of preparation: January 2021

Jardiance SMC guidance card index image

Empagliflozin (Jardiance®) 10mg film-coated tablets SMC2396

Promotional material from the Boehringer Ingelheim and Lilly Alliance

The production of this Guidelines  summary card has been commissioned by the Boehringer Ingelheim and Lilly Alliance.
View Jardiance® (empagliflozin) prescribing and adverse event reporting information for Great Britain and Northern Ireland.
PC-GB-105815 October 2021

Evenity index image

Romosozumab▼ (Evenity®) 105mg solution for injection in prefilled pen SMC2280

Commissioned by UCB Pharma Ltd

The production of this Guidelines card has been commissioned by UCB Pharma Ltd. 
Amgen and UCB Pharma Ltd are co-developing Evenity®.
View prescribing information and adverse event reporting
UK-P-RM-OP-2000095 December 2020

Resources (which contain promotional information) provided by Norgine.
View TARGAXAN ® (rifaximin-α) prescribing and adverse events reporting information
UK-HEP-XIF-2100027 Date of preparation: October 2021
  • Best practice in hepatic encephalopathy

  • Consensus statement: identification and management of hepatic encephalopathy